Zyprexa reps told to "neutralize" diabetes link

Documents unsealed in Alaska show that Eli Lilly sales reps touting Zyprexa were told to "neutralize the diabetes/hyperglycemia issue" that arose when doctors started pointing out that the drug might lead to the disease. "The competition wins when we are distracted into talking about diabetes," the documents state. Lilly says it hasn't downplayed Zyprexa's risks and that the documents are "a tiny fraction" of those provided as part of the Alaska lawsuit over the drug. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.